EGFR and neoplasm: A phase II study of preoperative gefitinib in clinical stage I non-small-cell lung cancer demonstrated that tumor shrinkage was frequently seen in women, neversmokers and the EGFR expression (proven by biopsy) was a strong predictor of response [44].